Monday, May 11, 2020 9:15:54 AM
$COCP;Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs
GlobeNewswire GlobeNewswire•May 11, 2020
– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program –
– Discussions ongoing with potential strategic partners for COVID-19 Coronavirus program –
– Collaboration with Merck to discover and develop certain proprietary influenza A/B antiviral agents remains ongoing –
– Supply chain delay in fully owned influenza A virus program –
– Norovirus program on track to complete proof-of-concept animal study model in Q4 2020 –
https://finance.yahoo.com/news/cocrystal-pharma-provides-covid-19-120510979.html
GlobeNewswire GlobeNewswire•May 11, 2020
– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program –
– Discussions ongoing with potential strategic partners for COVID-19 Coronavirus program –
– Collaboration with Merck to discover and develop certain proprietary influenza A/B antiviral agents remains ongoing –
– Supply chain delay in fully owned influenza A virus program –
– Norovirus program on track to complete proof-of-concept animal study model in Q4 2020 –
https://finance.yahoo.com/news/cocrystal-pharma-provides-covid-19-120510979.html
Recent COCP News
- Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/23/2026 09:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:30:27 PM
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive • GlobeNewswire Inc. • 04/02/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 12:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:30:22 PM
- Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:30:32 PM
- First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment • GlobeNewswire Inc. • 03/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:30:54 PM
- Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 • GlobeNewswire Inc. • 02/19/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:10:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 02:00:25 PM
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus • GlobeNewswire Inc. • 12/18/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 09:30:29 PM
- Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference • GlobeNewswire Inc. • 12/01/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 01:30:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 01:00:58 PM
- Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 11/14/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/30/2025 08:15:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 12:00:37 PM
